Citigroup
DTIL icon

Citigroup’s Precision BioSciences DTIL Stock Holding History

Citigroup’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95K Sell
12,082
-890
-7% -$6.26K ﹤0.01% 4717
2026
Q1 		$71.3K Buy
+12,972
New +$59.8K ﹤0.01% 4395
2025
Q3 		– Sell
-923
Closed -$3.88K – 6151
2025
Q2 		$3.88K Buy
+923
New +$4.55K ﹤0.01% 5308
2025
Q1 		– Sell
-13
Closed -$50 – 5675
2024
Q4 		$50 Buy
13
+12
+1,200% +$88 ﹤0.01% 5714
2024
Q3 		$9 Hold
1
– – ﹤0.01% 5622
2024
Q2 		$10 Hold
1
– – ﹤0.01% 5516
2024
Q1 		$14 Sell
1
-1,554
-100% -$19K ﹤0.01% 5554
2023
Q4 		$17K Hold
1,555
– – ﹤0.01% 5037
2023
Q3 		$15.9K Hold
1,555
– – ﹤0.01% 4452
2023
Q2 		$24.5K Hold
1,555
– – ﹤0.01% 4906
2023
Q1 		$35.2K Buy
+1,555
New +$51.2K ﹤0.01% 4360
2022
Q4 		– Sell
-33
Closed -$1K – 5812
2022
Q3 		$1K Sell
33
-120
-78% -$5.7K ﹤0.01% 5624
2022
Q2 		$7K Sell
153
-1,225
-89% -$71.9K ﹤0.01% 5489
2022
Q1 		$127K Sell
1,378
-4,625
-77% -$628K ﹤0.01% 4306
2021
Q4 		$1.33M Buy
6,003
+1,676
+39% +$468K ﹤0.01% 2966
2021
Q3 		$1.5M Sell
4,327
-3,502
-45% -$1.19M ﹤0.01% 2763
2021
Q2 		$2.94M Sell
7,829
-5,224
-40% -$1.57M ﹤0.01% 2363
2021
Q1 		$4.05M Buy
13,053
+11,900
+1,032% +$4.17M ﹤0.01% 1936
2020
Q4 		$289K Buy
1,153
+963
+507% +$236K ﹤0.01% 4697
2020
Q3 		$35K Sell
190
-379
-67% -$75.4K ﹤0.01% 5816
2020
Q2 		$142K Buy
569
+36
+7% +$7.88K ﹤0.01% 5286
2020
Q1 		$96K Buy
533
+104
+24% +$27.2K ﹤0.01% 5370
2019
Q4 		$179K Buy
429
+328
+325% +$103K ﹤0.01% 5275
2019
Q3 		$25K Sell
101
-97
-49% -$31.6K ﹤0.01% 6581
2019
Q2 		$79K Buy
198
+194
+4,850% +$78.1K ﹤0.01% 6077
2019
Q1 		$2K Buy
+4
New +$2.12K ﹤0.01% 7527

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citigroup's DTIL Position: Q2 2026 in Review

Citigroup reduced its Precision BioSciences (DTIL) stake by 6.9% in Q2 2026, selling an estimated $6.26K and leaving 12,082 shares worth $95K. The position accounts for ﹤0.01% of the portfolio, ranked #4717.

Citigroup first reported a position in DTIL in Q1 2019 and has held it in 26 quarters since. The position peaked at $4.05M in Q1 2021. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Citigroup held 12,082 shares of Precision BioSciences worth $95K as of Q2 2026.
  • Citigroup sold 890 Precision BioSciences shares in Q2 2026, an estimated $6.26K.
  • Precision BioSciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4717 holding.
  • Citigroup first reported a position in Precision BioSciences in Q1 2019 and has held it in 26 quarters since.
  • Citigroup's Precision BioSciences position peaked at $4.05M in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.